에이프로젠바이오로직스

003060KOSPI

47.0 / 100

Reference Date: 2026-10-23

Financial Score19.5 / 40

News Sentiment12.5 / 25

Momentum5.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Declined 13.3% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Aprogen BioLogics operates two business segments: a pharmaceutical division producing synthetic drugs and a biopharmaceutical division manufacturing biologics. Its Cheongju-based Osong facility boasts world-class antibody production capacity, capable of producing over 2.8 million liters of culture media annually. The affiliated company Aprogen Pharma focuses on drug distribution, though the group reported an operating loss as of 2023.

Number of Employees

445people

Average Salary

47.4M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

0.15Industry Average 1.207.0Point

Half of industry avg (excellent)

ROE

-51.29Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

28.93Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20250.5 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼7.1% (2-year basis)

Operating Profit Growth Rate

0.5 / 3

Avg ▼3.1% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -35.2% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position3.0Point

52w lower range (24%)

Current 1,423Won52-week high 5,10052-week low 235

1-month return1.0Point

1m -13.28% (falling)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

6 totalPositive 0Neutral 6Negative 0

Neutral주식등의대량보유상황보고서(일반)2026-10-08
Neutral타인에대한담보제공결정2026-10-08
Neutral투자유의안내 (관리종목지정 우려 예고)2026-10-06
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-10-02
Neutral주식등의대량보유상황보고서(일반)2026-10-02